Immunogenic Evaluation of MPEG-PCL & PLGA Nanoparticles Containing Klebsiella pneumoniae K2O1 Capsular Antigen in Pulmonary Infection Model of Mice.

Abstract

Klebsiella pneumoniae can cause destructive changes to human lungs if aspirated The present study aimed to evaluate the immunogenicity of the carriers of Poly lactic-co-glycolic acid (PLGA) and Methoxypoly(ethylene glycol) Poly(caprolactone) (MPEG-PCL) nanoparticles containing the capsular antigen of Klebsiella pneumoniae K2O1 in a model of pulmonary infection in mice as a vaccine candidate for protection against immunogenicity. Capsule antigen was extracted from K.pneumoniae K2O1 strain 1053 ATCC 10031 and transported with PLGA or MPEG-PCL nanoparticles as a vaccine candidate in an animal model. AFM and FT-IR were applied to measure and charge the PLGA, MPEG-PCL, PLGA-CPS, and MPEG-PCL-CPS molecules. The capsular polysaccharide was also used to evaluate the febrileness of the designed vaccine candidates based on the rabbits' pattern, and mortality due to the vaccine candidates was assessed in the mice. The results of FT-IR and the shape of the corresponding peaks confirmed the presence of antigen functional groups in the nanoparticle structure, as well as the formation of ester bonds. However, no fever was observed in the rabbits, and no mortality was observed in the mice. According to the results, the vaccine candidates designed to control the cause of pulmonary infections were effective in the liver, spleen, and lungs of the animals with the ability to enter the first stage of the clinical trial phase.